How many shares did BridgeBio repurchase in H1 2026?

The filing discloses only the dollar amount ($210.0 million) spent on repurchases, not the share count or average price paid. This level of detail is not provided in the current filing.

What is BridgeBio's current share-repurchase authorization?

The filing does not mention any formal board authorization for a share-repurchase program, nor does it disclose the remaining authorization capacity. Repurchases appear to be executed under an existing program, but specifics are not disclosed in this earnings release.

Did the new $1 billion preferred financing change the company's buyback strategy?

The filing does not address any changes to buyback policy resulting from the $1 billion preferred equity raise closed on July 1, 2026. The preferred financing was characterized as enabling the company to fund three product launches while continuing pipeline investment.

How do H1 2026 repurchases compare to the prior year?

In H1 2025, BridgeBio repurchased $48.3 million in common stock, compared to $210.0 million in H1 2026—more than a fourfold increase. This reflects stronger cash generation from Attruby commercial sales and a more aggressive approach to returning capital through repurchases.

What execution mechanism does BridgeBio use for buybacks?

The filing does not disclose whether repurchases are executed via Rule 10b-18 open-market purchases, accelerated share repurchase agreements, 10b5-1 plans, or other mechanisms. This information is not provided in the current earnings release.

Is BridgeBio experiencing accretion or dilution from stock compensation?

Despite $77.9 million in stock-based compensation expense in H1 2026 (up from $66.7 million in H1 2025), weighted-average shares outstanding grew only modestly from 190.3 million to 195.3 million, suggesting that buybacks are offsetting a significant portion of equity-compensation dilution.

BBIO 8-K Filed 2026-08-10 Execution disclosure

BridgeBio repurchased $210M in common stock during H1 2026

Company spent $210 million on buybacks in first half of 2026 under existing authorization, reducing share count amid commercial expansion.

MechanismNot specified

What the filing says

BridgeBio Pharma executed $210.0 million in common stock repurchases during the first half of 2026, as reported in the company's cash flow statement for the six months ended June 30, 2026. The buyback activity occurred concurrently with the company's commercial execution across multiple programs, including growth of Attruby net product revenues to $222.4 million in Q2 2026 alone and advancement of three late-stage pipeline candidates toward regulatory approval.

The filing does not disclose the specific number of shares repurchased, the average price paid per share, the execution mechanism (such as Rule 10b-18 open-market purchases or accelerated share repurchase agreements), or details of any formal authorization program. The repurchase activity is reported only as a cash outflow in the condensed consolidated statements of cash flows and is not the primary focus of this financial results announcement.

In the same period, BridgeBio also raised $1 billion in preferred equity financing (closed July 1, 2026) led by Sixth Street with participation from HealthCare Royalty, an affiliate of KKR, to fund three potential upcoming product launches while continuing investment in pipeline expansion.

Repurchase of common stock (210,003) [in thousands, six months ended June 30, 2026], as disclosed in the Condensed Consolidated Statements of Cash Flows. — BridgeBio Pharma, Inc. 8-K filing · View on SEC EDGAR →

What this means

BridgeBio's $210 million in H1 2026 share repurchases represent capital deployment during a period of significant commercial and clinical momentum. The company reported weighted-average shares outstanding of 195.3 million for the first half of 2026, down from 190.3 million in the prior-year period, indicating that despite new share issuance from equity compensation, repurchases have modestly reduced dilution. The buyback execution occurs against a backdrop of substantial cash generation from Attruby sales ($403 million net product revenue in H1 2026), though the company also reported operating cash burn of $268 million. The filing provides no forward guidance on buyback authorization levels, remaining capacity, or strategic intent, and does not specify whether repurchases will continue post-financing.

Frequently asked questions

How many shares did BridgeBio repurchase in H1 2026?: The filing discloses only the dollar amount ($210.0 million) spent on repurchases, not the share count or average price paid. This level of detail is not provided in the current filing.
What is BridgeBio's current share-repurchase authorization?: The filing does not mention any formal board authorization for a share-repurchase program, nor does it disclose the remaining authorization capacity. Repurchases appear to be executed under an existing program, but specifics are not disclosed in this earnings release.
Did the new $1 billion preferred financing change the company's buyback strategy?: The filing does not address any changes to buyback policy resulting from the $1 billion preferred equity raise closed on July 1, 2026. The preferred financing was characterized as enabling the company to fund three product launches while continuing pipeline investment.
How do H1 2026 repurchases compare to the prior year?: In H1 2025, BridgeBio repurchased $48.3 million in common stock, compared to $210.0 million in H1 2026—more than a fourfold increase. This reflects stronger cash generation from Attruby commercial sales and a more aggressive approach to returning capital through repurchases.
What execution mechanism does BridgeBio use for buybacks?: The filing does not disclose whether repurchases are executed via Rule 10b-18 open-market purchases, accelerated share repurchase agreements, 10b5-1 plans, or other mechanisms. This information is not provided in the current earnings release.
Is BridgeBio experiencing accretion or dilution from stock compensation?: Despite $77.9 million in stock-based compensation expense in H1 2026 (up from $66.7 million in H1 2025), weighted-average shares outstanding grew only modestly from 190.3 million to 195.3 million, suggesting that buybacks are offsetting a significant portion of equity-compensation dilution.

execution pharma-biotech cash-generation commercial-stage dilution-management preferred-financing

Source. This editorial summary is based on the SEC filing linked above. BuybackStocks aggregates and editorializes publicly available SEC EDGAR filings. Not investment advice. Past authorization announcements do not guarantee future repurchase activity or share price performance. See our full disclosures policy.